AT-130

• Description :

  AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells[1][2][3].

• CAS Number :

  [211364-06-6]

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis; HBV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection

• Assay Protocol :

  https://www.medchemexpress.com/at-130.html

• Concentration :

  10mM

• Purity :

  98.39

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(N/C(C(N1CCCCC1)=O)=C(Br)\C2=CC=CC=C2OC)C3=CC=C([N+]([O-])=O)C=C3

• Molecular Formula :

  C22H22BrN3O5

• Molecular Weight :

  488.33

• References & Citations :

  [1]William E Delaney 4th, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002 Sep;46 (9) :3057-60.|[2]R B Perni , et al. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg Med Chem Lett. 2000 Dec 4;10 (23) :2687-90.|[3]J J Feld, et al. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007 Nov;76 (2) :168-77.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported